Potential first-in-class, once-a-day, oral treatment of moderate-to-severe atopic dermatitis
- NCT10004 effectively reduces itch within 30-60 minutes in preclinical models
- NCT10004 significantly reduced rash by day 8 in repeat dose studies
- Broad activity across all wide spectrum of itch models
- Expected to enter clinical trials in 4Q2019
An advanced lead being evaluated as a next generation treatment of Dravet Syndrome.
Lead optimization program powered by new GABAA receptor structural data obtained by X-ray crystallography and cryo-electron microscopy, and cutting edge in silico models.